Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors

Volume: 196, Issue: 3
Published: Oct 10, 2021
Abstract
We read with interest Avivi et al.1 evaluating humoral response to two doses of BNT162b2 mRNA vaccine in multiple myeloma (MM) at manufacturer’s dosing interval. Suboptimal response to one2-4 and both doses5 of coronavirus disease 2019 (COVID-19) vaccines in MM have also been reported elsewhere. Administration of COVID-19 vaccines is important to protect this vulnerable cohort. Recognised humoral and cellular immune dysfunction in plasma cell...
Paper Details
Title
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors
Published Date
Oct 10, 2021
Volume
196
Issue
3
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.